Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial

Published:2021-10 Issue:10 Volume:22 Page:1438-1447
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Pinto Carmine,Zucali Paolo Andrea,Pagano Maria,Grosso Federica,Pasello Giulia,Garassino Marina Chiara,Tiseo Marcello,Soto Parra Hector,Grossi Francesco,Cappuzzo Federico,de Marinis Filippo,Pedrazzoli Paolo,Bonomi Maria,Gianoncelli Letizia,Perrino Matteo,Santoro Armando,Zanelli Francesca,Bonelli Candida,Maconi Antonio,Frega Stefano,Gervasi Erika,Boni Luca,Ceresoli Giovanni Luca

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

2. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial;Baas;Lancet,2021

3. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline;Kindler;J Clin Oncol,2018

4. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma;Zauderer;Lung Cancer,2014

5. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma;Ceresoli;Lung Cancer,2011

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unleashing precision: A review of targeted approaches in pleural mesothelioma;Critical Reviews in Oncology/Hematology;2024-11

2. Case report: complete response and long-term survival on third-line immunotherapy in patient with pleural mesothelioma;Frontiers in Oncology;2024-08-29

3. Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma;Journal of Surgical Oncology;2024-08-25

4. New Treatment for Pleural Mesothelioma;Haigan;2024-08-20

5. Newest therapeutic strategies impacting on rarest thoracic malignancies: The clinical case report of biphasic pleural mesothelioma;Heliyon;2024-08